Oppenheimer & Co. Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 10.0% during the first quarter, Holdings Channel reports. The firm owned 248,036 shares of the company’s stock after selling 27,691 shares during the period. Johnson & Johnson accounts for 0.9% of Oppenheimer & Co. Inc.’s portfolio, making the stock its 12th largest position. Oppenheimer & Co. Inc.’s holdings in Johnson & Johnson were worth $30,892,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Lau Associates LLC boosted its position in shares of Johnson & Johnson by 12.8% in the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock worth $5,839,000 after buying an additional 5,335 shares during the period. Loomis Sayles & Co. L P boosted its position in shares of Johnson & Johnson by 396.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 110,823 shares of the company’s stock worth $12,768,000 after buying an additional 88,510 shares during the period. Jackson Grant Investment Advisers Inc. boosted its position in shares of Johnson & Johnson by 7.3% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock worth $1,627,000 after buying an additional 957 shares during the period. Burke & Herbert Bank & Trust Co. boosted its position in shares of Johnson & Johnson by 2.6% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after buying an additional 1,218 shares during the period. Finally, Independent Advisor Alliance bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $4,035,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) traded up 0.92% during midday trading on Friday, reaching $134.32. The company had a trading volume of 1,220,550 shares. The stock has a market capitalization of $360.51 billion, a PE ratio of 22.73 and a beta of 0.78. The stock’s 50 day moving average is $133.18 and its 200-day moving average is $126.16. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.74 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.52%. Johnson & Johnson’s payout ratio is currently 56.76%.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Stake Reduced by Oppenheimer & Co. Inc.” was posted by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/08/11/johnson-johnson-jnj-stake-reduced-by-oppenheimer-co-inc.html.

JNJ has been the topic of a number of recent analyst reports. Morgan Stanley raised their target price on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, July 5th. BidaskClub cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 1st. Vetr cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.54 target price on the stock. in a report on Monday, May 1st. Jefferies Group LLC restated a “hold” rating and set a $140.00 target price on shares of Johnson & Johnson in a report on Friday, June 16th. Finally, Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $133.72.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.